Atlas market file · Equity · United States
aTYR PHARMA INCATYR
- Last close
- 0.502
- Change
- -5.10%
- 96-bar range
- 0.395 – 1.05
- As of
- 6 Aug 2026
aTYR PHARMA INC is a biological products, (no diagnostic substances) issuer listed as ATYR on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
ATYR
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-73.44% over the window).
Source rail: Yahoo Finance chart API (ATYR). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for ATYR. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
ATYR public profile
Biological products, (no diagnostic substances) issuer. aTYR PHARMA INC is connected to current market context, cited company sources and its retained research file.
aTYR PHARMA INC trades as ATYR on NASDAQ. aTYR PHARMA INC (ATYR) has a latest verified close of 0.502, down 5.10%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files ATYR under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for aTYR PHARMA INC today
aTYR Pharma Inc (ATYR) closed 2026’s second quarter with just $10M in cash and a $10.8M net loss, burning through capital as its lead drug candidate Efzofitimod remains unproven. The company reported negligible revenue ($190K in 2025) and relies on equity sales and debt to fund operations, per its March 2026 10-Q filing.
The San Diego-based biotech’s entire thesis hinges on Efzofitimod, an immunomodulatory therapy for systemic sclerosis-related interstitial lung disease (SSC-ILD). Clinical trials listed on its website show the Phase 2 EFZO-CONNECT™ study is ongoing, but the drug failed its primary endpoint in the prior EFZO-FIT trial last September. The company’s June 2026 investor presentation emphasizes ‘quality of life’ metrics but provides no new efficacy data.
Insider activity has spiked recently, with three Schedule 13G/A amendments filed since May 2026 adjusting ownership stakes. Meanwhile, operating cash flow remains deeply negative (-$12.5M in Q1 2026), and the firm’s diluted shares outstanding now total 98M. The stock’s $150M market cap assumes a high probability of regulatory success for Efzofitimod-a risky bet given its trial history.
Technical traders note ATYR’s 52-week range of $0.50-$8.20, though volume remains thin (average $2M daily). No major catalysts are scheduled until the EFZO-CONNECT results, expected in 2027. Until then, the stock depends on dilution-driven financing and the enduring optimism of biotech speculators.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
ATYR technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on ATYR
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep ATYR research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
ATYR FAQ
What is aTYR PHARMA INC (ATYR)?aTYR PHARMA INC (ATYR) has a latest verified close of 0.502, down 5.10%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed...
aTYR PHARMA INC (ATYR) has a latest verified close of 0.502, down 5.10%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for ATYR?aTYR PHARMA INC (ATYR) has a latest verified close of 0.502, down 5.10%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks...
aTYR PHARMA INC (ATYR) has a latest verified close of 0.502, down 5.10%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files ATYR under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the ATYR page updated?The ATYR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The ATYR public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for ATYR?The ATYR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ATYR. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The ATYR file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:ATYR. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on ATYR?Yes. The workstation can open ATYR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open ATYR, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this ATYR page investment advice?No. The ATYR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The ATYR page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →